|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To our knowledge, this is the first demonstration that MUC18 is involved in cell signaling regulating the expression of Id-1 and ATF-3, thus contributing to melanoma metastasis.
|
21467165 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD146 (MCAM) is associated with an advanced tumor stage in melanoma, prostate cancer and ovarian cancer.
|
19123925 |
2009 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To establish an immunocompetent syngeneic mouse model that would greatly facilitate our understanding of the role of MUC18 in the metastatic behavior of melanoma, we cloned and characterized the mouse MUC18 (muMUC18) cDNA gene.
|
11255016 |
2001 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previously, we have shown that the progression of human melanoma to the metastatic phenotype is associated with loss of AP-2 expression and deregulation of target genes such as MUC18/MCAM, c-KIT, and MMP-2.
|
12789289 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Wnt5a signaling results in acyl protein thioesterase 1 (APT1) mediated depalmitoylation of pro-metastatic cell adhesion molecules CD44 and MCAM, resulting in increased melanoma invasion.
|
29648538 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the other hand, MCAM and beta3 integrin are the two adhesion molecules that play a pivotal role in melanoma cell migration and invasion, and for this reason, may represent valuable targets for melanoma therapy.
|
16969099 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of melanoma-associated genes (N-cadherin, MUC-18, integrin β3, α3, α5, αv, SLUG, TBX3, HIF1-α, BMP-4 and bFGF) was enhanced in MBrc which were de-differentiated out of melanocytes.
|
21496114 |
2011 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results showed that GCNT3 is an upstream regulator of MCAM protein and indicate the possibility of a potential molecular target in melanoma therapeutics through abrogation of the S100A8/A9-MCAM axis.
|
28923134 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
On the other hand, MCAM and beta3 integrin are the two adhesion molecules that play a pivotal role in melanoma cell migration and invasion, and for this reason, may represent valuable targets for melanoma therapy.
|
16969099 |
2006 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate here that human T cells, upon activation, neo-express the melanoma metastasis-associated surface molecule MUC18/melanoma cell adhesion molecule (MCAM).
|
9036955 |
1997 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to address this question, 2 MCAM negative human melanoma cell lines, SK-2 and XP44RO(Mel), were transfected with MCAM-encoding cDNA.
|
10362144 |
1999 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MUC18-encoding cDNA clones were obtained by screening a human melanoma phage lambda expression library with monoclonal antibodies produced against the denatured antigen.
|
2602381 |
1989 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>89</sup>Zr-Df-YY146 PET readily detects CD146-positive A375 melanomas.
|
31065511 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
These observations further suggest a role for MUC18 in uveal melanoma growth; moreover, interactions between MUC18-positive melanoma cells and vasculature may be important for the hematogenous spread of cells during metastases.
|
17786470 |
2007 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As MUC18 has proangiogenic potency in melanoma and prostate cancer this study investigated the role of MUC18 in patients with stenotic or dilatative arteriosclerotic disease as a putative biochemical marker.
|
25729916 |
2015 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
S100A8/A9-MCAM binding activates mitogen-activated protein kinase kinase kinase 8 (MAP3K8), also termed TPL2, leading to strong activation of the transcription factor ETV4 and subsequent induction of matrix metalloproteinase-25 (MMP25), and finally to induction of melanoma lung tropic metastasis.
|
30904617 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this prospect article, we summarize our data on the role of AP-2 and CREB/ATF-1 in the progression of human melanoma and report on the development of new fully human antibodies anti-MCAM/MUC18 and anti-IL-8 which could serve as new modalities for the treatment of melanoma.
|
15523674 |
2005 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CD146 (also known as MCAM, MUC-18, Mel-CAM) was initially reported in 1987, as a protein crucial for the invasiveness of malignant melanoma.
|
31826047 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Of the genes identified, seven genes: galectin 3 (Lgals3), melanoma cell adhesion molecule (Mcam), fibronectin 1 (Fn1), signal transducer and activator of transcription 3 (Stat3), microphthalmia-associated transcription factor (Mitf), max interacting protein 1 (Max1), and non-metastatic cells 1, protein (NM23A) expressed in (Nme1) are known to be associated with melanoma, but have not yet been reported as being regulated by hypoxia in human melanoma cells.
|
21912348 |
2011 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To determine whether atypical, compared to benign nevi, from patients with a clinical history of malignant melanoma reveal molecular changes, we analyzed these lesions for the expression of two growth factors (basic fibroblast growth factor and transforming growth factor alpha), their receptors (fibroblast growth factor receptor-1 and epidermal growth factor receptor), and two cell adhesion molecules (MUC18 and alpha v beta 3 integrin), all of which are expressed in primary and metastatic melanomas.
|
8959342 |
1996 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The mechanism for up-regulation of MCAM/MUC18 during melanoma progression is unknown.
|
9632718 |
1998 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding.
|
27151304 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Various approaches for targeting CD146 in melanoma cells have been exploited and CD146 has been shown to be a promising target for antitumor therapy.
|
23370332 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To provide direct evidence that MCAM plays a role in tumor growth and metastasis of human melanoma, the nonmetastatic MCAM-negative primary cutaneous melanoma SB-2 cells were transfected with MCAM cDNA and analyzed subsequently for changes in their tumorigenic and metastatic potential.
|
9187135 |
1997 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-immunoprecipitation and bioluminescence resonance energy transfer (BRET) experiments indicate that hShrm1 and MCAM interact in vivo and by immunofluorescence microscopy some co-localization of these proteins is observed. hShrm1 partly co-localises with beta-actin and is found in the Triton X-100 insoluble fraction of melanoma cell extracts.
|
19137261 |
2009 |